IGAN1
MCID: IGN003
MIFTS: 39

Iga Nephropathy 1 (IGAN1)

Categories: Genetic diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Iga Nephropathy 1

MalaCards integrated aliases for Iga Nephropathy 1:

Name: Iga Nephropathy 1 57
Berger Disease 57 73 29 6
Iga Nephropathy, Susceptibility to, 1 57 29
Igan 57 72
Iga Nephropathy, Susceptibility to, Type 1 39
Iga Glomerulonephritis 70
Nephritis, Iga Type 57
Iga Nephropathy 72
Igan1 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
?autosomal dominant

Miscellaneous:
histologic features overlap with henoch-schonlein purpura (hspn)
incidence 5-50 per million (children) and 10-40 per million (adults)


HPO:

31
iga nephropathy 1:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



External Ids:

OMIM® 57 161950
OMIM Phenotypic Series 57 PS161950
UMLS 70 C0017661

Summaries for Iga Nephropathy 1

OMIM® : 57 End-stage renal disease (ESRD) is a major public health problem, affecting 1 in 1,000 individuals and with an annual death rate of 20% despite dialysis treatment. IgA nephropathy (IgAN) is the most common form of glomerulonephritis, a principal cause of ESRD worldwide, affecting up to 1.3% of the population. Kidneys of patients with IgA nephropathy show deposits of IgA-containing immune complexes with proliferation of the glomerular mesangium. Typical clinical features include onset before age 40 with hematuria and proteinuria, and episodes of gross hematuria following mucosal infections are common; 30% of patients develop progressive renal failure. Although not generally considered a hereditary disease, striking ethnic variation in prevalence (Julian et al., 1985; D'Amico, 1987) and familial clustering (Scolari et al., 1999), along with subclinical renal abnormalities among relatives of cases, suggest a genetic component (Gharavi et al., 2000). (161950) (Updated 05-Apr-2021)

MalaCards based summary : Iga Nephropathy 1, also known as berger disease, is related to iga nephropathy 3 and iga nephropathy 2. An important gene associated with Iga Nephropathy 1 is IGAN1 (IgA Nephropathy). The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are arthralgia and hypertension

UniProtKB/Swiss-Prot : 72 IgA nephropathy: Most common primary glomerulonephritis, which is partly due to aberrant or incomplete galactosylation of IgA1 molecules.

Wikipedia : 73 IgA nephropathy (IgAN), also known as Berger's disease (/bɛərˈʒeɪ/) (and variations), or synpharyngitic... more...

Related Diseases for Iga Nephropathy 1

Diseases in the Iga Nephropathy 1 family:

Iga Nephropathy 2 Iga Nephropathy 3

Diseases related to Iga Nephropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 iga nephropathy 3 11.7
2 iga nephropathy 2 11.4
3 hematuria, benign familial 11.1
4 loin pain hematuria syndrome 11.1
5 tonsillitis 10.8
6 membranous nephropathy 10.8
7 focal segmental glomerulosclerosis 10.7
8 crescentic glomerulonephritis 10.7
9 acute kidney failure 10.7
10 rapidly progressive glomerulonephritis 10.6
11 spondyloarthropathy 1 10.5
12 inflammatory spondylopathy 10.5
13 spondylitis 10.5
14 microvascular complications of diabetes 3 10.5
15 microvascular complications of diabetes 4 10.5
16 microvascular complications of diabetes 6 10.5
17 microvascular complications of diabetes 7 10.5
18 autoimmune disease 10.5
19 proteasome-associated autoinflammatory syndrome 1 10.5
20 hyperuricemia 10.5
21 malignant hypertension 10.5
22 crohn's disease 10.5
23 interstitial nephritis 10.5
24 liver cirrhosis 10.5
25 lupus erythematosus 10.4
26 amyloidosis 10.4
27 systemic lupus erythematosus 10.4
28 polycystic kidney disease 10.4
29 sarcoidosis 1 10.4
30 renal hypertension 10.4
31 pustulosis of palm and sole 10.4
32 psoriasis 10.4
33 celiac disease 1 10.4
34 arteriolosclerosis 10.4
35 acute kidney tubular necrosis 10.4
36 uveitis 10.4
37 proteinuria, chronic benign 10.3
38 inflammatory bowel disease 10.3
39 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
40 pre-eclampsia 10.3
41 lipoid nephrosis 10.3
42 tetanus 10.3
43 glomerulonephritis 10.3
44 nephrosclerosis 10.3
45 arteriosclerosis 10.3
46 immune-complex glomerulonephritis 10.3
47 thrombotic microangiopathy 10.3
48 glomerular disease 10.3
49 hemolytic-uremic syndrome 10.3
50 pharyngitis 10.3

Graphical network of the top 20 diseases related to Iga Nephropathy 1:



Diseases related to Iga Nephropathy 1

Symptoms & Phenotypes for Iga Nephropathy 1

Human phenotypes related to Iga Nephropathy 1:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 arthralgia 31 occasional (7.5%) HP:0002829
2 hypertension 31 HP:0000822
3 proteinuria 31 HP:0000093
4 hematuria 31 HP:0000790
5 purpura 31 HP:0000979
6 stage 5 chronic kidney disease 31 HP:0003774
7 nephritis 31 HP:0000123
8 iga deposition in the glomerulus 31 HP:0000794

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
proteinuria
hematuria, macroscopic and microscopic

Immunology:
serum circulating immune complexes contain galactose-deficient iga1

Genitourinary Kidneys:
proteinuria
hematuria, microscopic
hematuria, macroscopic (seen in children and young adults coincident with mucosal infection)
galactose-deficient iga1 deposits in the glomerular mesangium, with or without igm and igg
glomerular crescents (rare), seen on biopsy
more
Skeletal:
arthralgia (in some patients)

Clinical features from OMIM®:

161950 (Updated 05-Apr-2021)

Drugs & Therapeutics for Iga Nephropathy 1

Drugs for Iga Nephropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Probucol Approved, Investigational Phase 4 23288-49-5 4912
9
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
10
rituximab Approved Phase 4 174722-31-7 10201696
11
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
12
Azathioprine Approved Phase 4 446-86-6 2265
13
Ramipril Approved Phase 4 87333-19-5 5362129
14
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
15
Canagliflozin Approved Phase 4 842133-18-0
16
Empagliflozin Approved Phase 4 864070-44-0
17
Losartan Approved Phase 4 114798-26-4 3961
18
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
19
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
20
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
24
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
25
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
26
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
27
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
28
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
29 Cassava Phase 4
30 interferons Phase 4
31 Interferon-alpha Phase 4
32 Mitogens Phase 4
33 Antimetabolites Phase 4
34 Antibiotics, Antitubercular Phase 4
35 Anti-Infective Agents Phase 4
36 Anti-Bacterial Agents Phase 4
37 Antitubercular Agents Phase 4
38 Omega 3 Fatty Acid Phase 4
39 Vasoconstrictor Agents Phase 4
40 Nutrients Phase 4
41 Trace Elements Phase 4
42 Micronutrients Phase 4
43 Vitamins Phase 4
44 Calcium, Dietary Phase 4
45 Antimalarials Phase 4
46 Antiparasitic Agents Phase 4
47 Antiprotozoal Agents Phase 4
48 Antioxidants Phase 4
49 Anticholesteremic Agents Phase 4
50 Lipid Regulating Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
2 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
3 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
4 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
5 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
6 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
7 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
8 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
9 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
10 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
11 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
12 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
13 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
14 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
15 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
16 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
17 A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy Recruiting NCT04525729 Phase 4 Rituximab;RAS 2410
18 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
19 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
20 Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Not yet recruiting NCT04662723 Phase 4 Corticosteroid;Renin-angiotensin sytem blockers;Sodium-glucose cotransporter 2 inhibitor
21 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
22 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Terminated NCT02523768 Phase 4 ATG-F;Simulect
23 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
24 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
25 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy -- A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
26 Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
27 A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Completed NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
28 An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Completed NCT02282930 Phase 3 ACTH (Acthar) Gel
29 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
30 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
31 Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
32 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
33 A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
34 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) Recruiting NCT03608033 Phase 3
35 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
36 A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
37 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Recruiting NCT04578834 Phase 3 Placebo;LNP023
38 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function Recruiting NCT04573478 Phase 3 Atrasentan;Placebo
39 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of End-stage Renal Disease (TCM-WINE) Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie herbal compound;Immunosuppressants
40 Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
41 A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label LNP023 in Patients With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301 Not yet recruiting NCT04557462 Phase 3 LNP023
42 An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301 Not yet recruiting NCT04541043 Phase 3 Nefecon
43 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
44 A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
45 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Withdrawn NCT00599963 Phase 3 paricalcitol
46 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
47 Fecal Microbiota Transplantation for Refractory IgA Nephropathy: a Prospective, Single-center, Cohort Study Unknown status NCT03633864 Phase 2
48 Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
49 Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy Completed NCT00004448 Phase 2 omega-3 fatty acids;prednisone
50 Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy Completed NCT01224028 Phase 2 Tacrolimus;Placebo

Search NIH Clinical Center for Iga Nephropathy 1

Genetic Tests for Iga Nephropathy 1

Genetic tests related to Iga Nephropathy 1:

# Genetic test Affiliating Genes
1 Berger Disease 29
2 Iga Nephropathy, Susceptibility to, 1 29

Anatomical Context for Iga Nephropathy 1

MalaCards organs/tissues related to Iga Nephropathy 1:

40
Kidney, Liver, T Cells, Myeloid

Publications for Iga Nephropathy 1

Articles related to Iga Nephropathy 1:

(show top 50) (show all 75)
# Title Authors PMID Year
1
IgA nephropathy. 57
23782179 2013
2
Genome-wide association study identifies susceptibility loci for IgA nephropathy. 57
21399633 2011
3
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. 57
18172551 2008
4
Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. 57
17634434 2007
5
Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. 57
17186473 2006
6
Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. 57
15067315 2004
7
Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. 57
14616762 2003
8
Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. 57
12746403 2003
9
Association of the CD14 gene -159C polymorphism with progression of IgA nephropathy. 57
12566518 2003
10
Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients. 57
12740691 2003
11
IgA nephropathy. 57
12213946 2002
12
Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. 57
11828340 2002
13
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. 57
11532091 2001
14
Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. 57
11231363 2001
15
Polymorphism in promoter region of Fcalpha receptor gene in patients with IgA nephropathy. 57
11281451 2001
16
IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. 57
11062479 2000
17
Identification and characterization of the promoter for the gene encoding the human myeloid IgA Fc receptor (FcalphaR, CD89). 57
11003388 2000
18
Evidence for genetic factors in the development and progression of IgA nephropathy. 57
10792601 2000
19
Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. 57
10470078 1999
20
Familial clustering of IgA nephropathy: further evidence in an Italian population. 57
10213640 1999
21
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 57
9259580 1997
22
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. 57
9264010 1997
23
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 57
7593601 1995
24
Familial cases of Berger's disease and anaphylactoid purpura: more frequent than previously thought. 57
2757072 1989
25
IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? 57
3337116 1988
26
The commonest glomerulonephritis in the world: IgA nephropathy. 57
3329736 1987
27
A major gene model for the familial aggregation of plasma IgA concentration. 57
3480689 1987
28
Dietary gluten and primary IgA nephropathy. 57
3762637 1986
29
Low incidence of IgA nephropathy in blacks. 57
4087701 1985
30
Familial IgA nephropathy. Evidence of an inherited mechanism of disease. 57
3855328 1985
31
Immunoglobulin A nephropathy. Quantitative immunohistomorphometry of the tonsillar plasma cells evidences an inversion of the immunoglobulin A versus immunoglobulin G secreting cell balance. 57
6406547 1983
32
IgA nephropathy. Correlation of clinical and histologic features. 57
6218335 1983
33
Family study in IgA nephritis: the possible role of HLA antigens. 57
7404656 1980
34
Mesangial IgA glomerulonephritis in HLA-identical brothers. 57
428154 1979
35
IGA nephropathy in HLA-identical siblings. 57
734738 1978
36
Mesangial IgA glomerulonephritis and HLA antigens. 57
661897 1978
37
HLA-Bw35 and mesangial IgA glomerulonephritis. 57
643002 1978
38
IgA nephropathy. 57
4601708 1974
39
IgA glomerular deposits in renal disease. 57
4107073 1969
40
A boy with IgA nephropathy complicated by tubulointerstitial nephritis and uveitis (TINU) syndrome. 61
24075025 2015
41
Clinicopathological analysis of 155 patients with persistent isolated hematuria. 61
25264882 2014
42
Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. 61
23269570 2013
43
Prevalence of nephropathies in children and adolescents and alterations in renal biopsies in Minas Gerais, Brazil, from 1996 to 2010. 61
22658343 2013
44
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. 61
21448451 2011
45
Indication criteria for tonsillectomy in IgA nephropathy patients. 61
21865688 2011
46
[Renal involvement in Behcet's disease]. 61
20517850 2010
47
Preemptive living donor renal transplantation: a single-center experience. 61
19765429 2009
48
[Outcome of HIV-infected patients of peritoneal dialysis: experience in a center and literature review]. 61
18816208 2008
49
[Percutaneous kidney biopsy: eight years-experience]. 61
15636724 2004
50
[Pathogenesis of immune glomerulonephritis]. 61
15008213 2003

Variations for Iga Nephropathy 1

ClinVar genetic disease variations for Iga Nephropathy 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIGR NM_002644.4(PIGR):c.1739C>T (p.Ala580Val) SNV Uncertain significance 13526 rs291102 GRCh37: 1:207106478-207106478
GRCh38: 1:206933133-206933133

Expression for Iga Nephropathy 1

Search GEO for disease gene expression data for Iga Nephropathy 1.

Pathways for Iga Nephropathy 1

GO Terms for Iga Nephropathy 1

Sources for Iga Nephropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....